Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

1.080 -0.010 (-0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,121,277
Open 1.120
Bid (Size) 1.080 (10)
Ask (Size) 1.200 (1)
Prev. Close 1.090
Today's Range 1.080 - 1.140
52wk Range 1.000 - 2.650
Shares Outstanding 994,213,968
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical... 
Via Newsfile
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1... 
Via Newsfile

Performance

YTD
-35.33%
-35.33%
1 Month
-22.30%
-22.30%
3 Month
-18.18%
-18.18%
6 Month
-44.62%
-44.62%
1 Year
-35.33%
-35.33%

More News

Read More
Earnings Scheduled For May 12, 2023
Via Benzinga
Recap: Adaptimmune Therapeutics Q1 Earnings
Via Benzinga
Earnings Preview For Adaptimmune Therapeutics
Via Benzinga
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Via Benzinga
Adaptimmune Therapeutics's Earnings Outlook
Via Benzinga
Adaptimmune Reports First Quarter Financial Results and Business Update
Via Newsfile
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
Via Newsfile
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
Via The Motley Fool
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
Via Newsfile
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
From Brodsky & Smith LLC
Via GlobeNewswire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Why Is TCR2 Therapeutics Stock Trading Higher Today?
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
Via Spotlight Growth
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
Via InvestorPlace
ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
Via Newsfile
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Via Newsfile
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
Via Newsfile
Adaptimmune Announces Changes to Board of Directors
Via Newsfile
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.